Biocept Revenue and Competitors

Location

$43.2M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Biocept's estimated annual revenue is currently $15M per year.(i)
  • Biocept's estimated revenue per employee is $192,308
  • Biocept's total funding is $43.2M.

Employee Data

  • Biocept has 78 Employees.(i)
  • Biocept grew their employee count by -26% last year.

Biocept's People

NameTitleEmail/Phone
1
VP, OperationsReveal Email/Phone
2
VP Laboratory OperationsReveal Email/Phone
3
SVP, Corporate DevelopmentReveal Email/Phone
4
VP Clinical DevelopmentReveal Email/Phone
5
VP Human ResourcesReveal Email/Phone
6
VP, Controller and principal accounting officerReveal Email/Phone
7
Senior Director Human ResourcesReveal Email/Phone
8
Sr. Director, Translational Research and CLIA DevelopmentReveal Email/Phone
9
Senior Director, OperationsReveal Email/Phone
10
Chief Operating OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Biocept?

Biocept is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. The Company\'s patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in plasma (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient\'s disease and therapeutic options.

keywords:Biotechnology, Healthcare

$43.2M

Total Funding

78

Number of Employees

$15M

Revenue (est)

-26%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Biocept News

2022-03-30 - Biocept Reports Inducement Grants Under Nasdaq Listing ...

Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for...

2022-03-30 - Biocept Reports 2021 Fourth Quarter and Full Year Financial ...

Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for...

2022-03-22 - Biocept Reports Unaudited 2021 Revenue and Year-End ...

Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for...

2021-11-16 - Biocept : Reports Third Quarter 2021 Financial Results - Form 8-K

Biocept Reports Third Quarter 2021 Financial Results • Revenues for the third quarter of $17.5 million, up 165% over prior-year quarter, driven by increased RT-PCR COVID-19 testing, resulting in profitability; cash balance of $27.7 million at quarter-end • Robust CNSide™ sequential-quarter v ...

2021-08-16 - Biocept : Reports Second Quarter 2021 Financial Results (Form 8-K)

Biocept Reports Second Quarter 2021 Financial Results • Second quarter revenues of $12.0 million driven by RT-PCR COVID-19 testing • Continued sequential-quarter CNSide™ volume growth with customer base expanding to more than 30 leading U.S. academic institutions, including multiple repeat u ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$12.1M783%N/A
#2
$9.6M78-5%N/A
#3
$7.5M7842%N/A
#4
$19.1M785%N/A
#5
$12.5M7810%N/A